Amgen Announces Cochrane Findings: ESAs Increase Risk Of On-Study Death
Something was missing from a press release announcing the Cochrane Collaboration’s preliminary result from a pooled analysis of ESA studies.
That something was comment from the investigators who conducted the patient-level meta-analysis. The only quote belonged to Roger Perlmutter, executive vice president for Research and Development at Amgen Inc., one of the three companies that provided the randomized trial data for the pooled analysis.
It was, in fact, Amgen that issued the press release about the Cochrane findings.